Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
Comparison of the Efficacy and Safety of Step-wise Addition of Short Acting Insulin Analogue Insulin Aspart to Once Daily Insulin Detemir and Oral Anti-diabetic Treatment in Patients With Type 2 Diabetes
This trial is conducted in Europe, Africa and the United States of America (USA).
The aim of this trial is to compare the safety and efficacy of two different insulin treatments, the "basic" and the "advanced" treatment in type 2 diabetes.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Århus C, Denemarken, 8000
- Novo Nordisk Investigational Site
-
-
-
-
-
Espoo, Finland, FI-02650
- Novo Nordisk Investigational Site
-
Oulu, Finland, FI-90220
- Novo Nordisk Investigational Site
-
Oulu, Finland, FI-90100
- Novo Nordisk Investigational Site
-
Tampere, Finland, 33100
- Novo Nordisk Investigational Site
-
Vaasa, Finland, FIN-61500
- Novo Nordisk Investigational Site
-
Vantaa, Finland, FI-01620
- Novo Nordisk Investigational Site
-
-
-
-
-
Le Creusot, Frankrijk, 71200
- Novo Nordisk Investigational Site
-
Nanterre, Frankrijk, 92014
- Novo Nordisk Investigational Site
-
Narbonne, Frankrijk, 11108
- Novo Nordisk Investigational Site
-
Pointe à Pitre, Frankrijk, 97159
- Novo Nordisk Investigational Site
-
Venissieux, Frankrijk, 69200
- Novo Nordisk Investigational Site
-
-
-
-
-
Den Bosch, Nederland, 5216 GC
- Novo Nordisk Investigational Site
-
Eindhoven, Nederland, 5631 BM
- Novo Nordisk Investigational Site
-
Etten-Leur, Nederland, 4872 LP
- Novo Nordisk Investigational Site
-
Hulst, Nederland, 4561 NV
- Novo Nordisk Investigational Site
-
Utrecht, Nederland, 3563 AZ
- Novo Nordisk Investigational Site
-
Woerden, Nederland, 3443 GG
- Novo Nordisk Investigational Site
-
-
-
-
-
Jessheim, Noorwegen, 2050
- Novo Nordisk Investigational Site
-
Oslo, Noorwegen, 0160
- Novo Nordisk Investigational Site
-
Sarpsborg, Noorwegen, 1702
- Novo Nordisk Investigational Site
-
Stavanger, Noorwegen, 4011
- Novo Nordisk Investigational Site
-
Tromsø, Noorwegen, 9038
- Novo Nordisk Investigational Site
-
Tønsberg, Noorwegen, 3116
- Novo Nordisk Investigational Site
-
-
-
-
-
Moscow, Russische Federatie, 119435
- Novo Nordisk Investigational Site
-
Moscow, Russische Federatie, 127644
- Novo Nordisk Investigational Site
-
Moscow, Russische Federatie, 123448
- Novo Nordisk Investigational Site
-
-
-
-
-
Cáceres, Spanje, 10004
- Novo Nordisk Investigational Site
-
Inca, Spanje, 07300
- Novo Nordisk Investigational Site
-
Madrid, Spanje, 28034
- Novo Nordisk Investigational Site
-
Mostoles - Madrid -, Spanje, 28935
- Novo Nordisk Investigational Site
-
Málaga, Spanje, 29010
- Novo Nordisk Investigational Site
-
Mérida, Spanje, 06800
- Novo Nordisk Investigational Site
-
Santiago de Compostela, Spanje, 15706
- Novo Nordisk Investigational Site
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 1LD
- Novo Nordisk Investigational Site
-
Coventry, Verenigd Koninkrijk, CV2 2DX
- Novo Nordisk Investigational Site
-
Livingstone, Verenigd Koninkrijk, EH54 6PP
- Novo Nordisk Investigational Site
-
Llanelli, Verenigd Koninkrijk, SA14 8QF
- Novo Nordisk Investigational Site
-
Llantrisant, Verenigd Koninkrijk, CF72 8XR
- Novo Nordisk Investigational Site
-
Reading, Verenigd Koninkrijk, RG7 3SQ
- Novo Nordisk Investigational Site
-
Rugby, Verenigd Koninkrijk, CV22 5PX
- Novo Nordisk Investigational Site
-
-
-
-
California
-
Fresno, California, Verenigde Staten, 93720
- Novo Nordisk Investigational Site
-
Mission Viejo, California, Verenigde Staten, 92691
- Novo Nordisk Investigational Site
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- Novo Nordisk Investigational Site
-
-
Georgia
-
Athens, Georgia, Verenigde Staten, 30606
- Novo Nordisk Investigational Site
-
Atlanta, Georgia, Verenigde Staten, 30318
- Novo Nordisk Investigational Site
-
-
Iowa
-
Des Moines, Iowa, Verenigde Staten, 50314-3027
- Novo Nordisk Investigational Site
-
-
New Jersey
-
Lawrenceville, New Jersey, Verenigde Staten, 08648
- Novo Nordisk Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, Verenigde Staten, 28803
- Novo Nordisk Investigational Site
-
-
Ohio
-
Dayton, Ohio, Verenigde Staten, 45439
- Novo Nordisk Investigational Site
-
Kettering, Ohio, Verenigde Staten, 45429
- Novo Nordisk Investigational Site
-
-
South Carolina
-
Greer, South Carolina, Verenigde Staten, 29651
- Novo Nordisk Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37411
- Novo Nordisk Investigational Site
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75230
- Novo Nordisk Investigational Site
-
Dallas, Texas, Verenigde Staten, 75390-9302
- Novo Nordisk Investigational Site
-
Dallas, Texas, Verenigde Staten, 75231
- Novo Nordisk Investigational Site
-
Houston, Texas, Verenigde Staten, 77030
- Novo Nordisk Investigational Site
-
San Antonio, Texas, Verenigde Staten, 78229
- Novo Nordisk Investigational Site
-
-
Virginia
-
Newport News, Virginia, Verenigde Staten, 23606
- Novo Nordisk Investigational Site
-
Richmond, Virginia, Verenigde Staten, 23294
- Novo Nordisk Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53209
- Novo Nordisk Investigational Site
-
-
-
-
-
Belgrade, Voormalig Servië en Montenegro, 11000
- Novo Nordisk Investigational Site
-
Nis, Voormalig Servië en Montenegro, 18000
- Novo Nordisk Investigational Site
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Zuid-Afrika, 1829
- Novo Nordisk Investigational Site
-
Johannesburg, Gauteng, Zuid-Afrika, 1818
- Novo Nordisk Investigational Site
-
Pretoria, Gauteng, Zuid-Afrika, 0001
- Novo Nordisk Investigational Site
-
-
-
-
-
Göteborg, Zweden, 417 17
- Novo Nordisk Investigational Site
-
Mölndal, Zweden, 431 80
- Novo Nordisk Investigational Site
-
Ängelholm, Zweden, 262 91
- Novo Nordisk Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Type 2 diabetes mellitus for more than 6 months
- HbA1c (glycosylated haemoglobin A1c) between 7.5 % and 10.0% at trial initiation (screening)
- BMI (Body Mass Index) less than 40 kg/m2
- Basal insulin treatment for at least 3 months (NPH once or twice daily, insulin glargine or detemir once daily)
- Treatment with one to 3 OADs
Exclusion Criteria:
- Known or suspected allergy to trial products or related products
- Women who are pregnant, are breast-feeding or intend to become pregnant within the next 48 weeks
- Previous participation in any trial including this for the last 6 months
- Use of more than 1 U/kg of basal insulin daily at trial initiation (screening)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Advanced
Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose).
The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
|
Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c.
(under the skin)
Administered 1 - 3 times daily, at largest prandial increment, injection s.c.
(under the skin)
Administered 1 - 3 times daily, at largest meals, injection s.c.
(under the skin)
|
|
Actieve vergelijker: Basic
Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose).
The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
|
Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c.
(under the skin)
Administered 1 - 3 times daily, at largest prandial increment, injection s.c.
(under the skin)
Administered 1 - 3 times daily, at largest meals, injection s.c.
(under the skin)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Glycosylated Haemoglobin A1c (HbA1c)
Tijdsspanne: week 36
|
Analysed for the full analysis set.
|
week 36
|
|
Glycosylated Haemoglobin A1c (HbA1c)
Tijdsspanne: week 36
|
Measured for the Per Protocol analysis set.
|
week 36
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hypoglycaemic Episodes
Tijdsspanne: Weeks 0-36
|
Number of hypoglycaemic episodes from Week 0 to Week 36, defined as major, minor or symptoms only.
Major if unable to treat her/himself.
Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L (56 mg/dL).
Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.
|
Weeks 0-36
|
|
Biochemistry: Serum Alanine Aminotransferase
Tijdsspanne: week 36
|
Alanine aminotransferase was measured in serum at week 36.
Serum samples were analysed at a central laboratory.
|
week 36
|
|
Haematology: Haemoglobin Measured in Blood
Tijdsspanne: week 36
|
Haemoglobin was measured in blood samples at week 36.
Blood samples were analysed at a central laboratory.
|
week 36
|
|
Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide
Tijdsspanne: week 36
|
High-sensitivity C-reactive peptide was measured in serum at week 36.
Serum samples were analysed at a central laboratory.
|
week 36
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Glucosemetabolismestoornissen
- Metabole ziekten
- Endocriene systeemziekten
- Suikerziekte
- Diabetes mellitus, type 2
- Hypoglycemische middelen
- Fysiologische effecten van medicijnen
- Insuline
- Insuline, Globin Zink
- Insuline Aspart
- Insuline, langwerkend
- Insuline degludec, combinatie van insuline aspart
- Insuline Detemir
Andere studie-ID-nummers
Andere studie-ID-nummers
- NN304-1833
- 2007-000123-18 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .